Innate Pharma Completes Phase 1 Enrollment Of Nectin-4 Exatecan ADC IPH4502, Guiding Dose Optimization With Year-End Preliminary Data Readout

Loading news article.

Innate Pharma Completes Phase 1 Enrollment Of Nectin-4 Exatecan ADC IPH4502, Guiding Dose Optimization With Year-End Preliminary Data Readout | WAPE

Article summary